The clinical, functional, and radiological effect of long-term used immunosuppressive therapy for post-COVID-19 interstitial lung disease
Immunosuppressive therapy in post-COVID-19-ILD
Keywords:
Immunosuppressive therapy, Interstitial lung diseases, Post-COVID-19Abstract
Background and aim: Persistent interstitial lung disease (ILD) after COVID-19 infection can lead to severe loss of respiratory function and a decrease in the quality of life. There is no consensus regarding the treatment of post-COVID-19-ILD. This study aims to investigate the effectiveness of immunosuppressive treatment for this group of patients. Methods: This retrospective observational study included patients diagnosed with post-COVID-19-ILD from 2021 to 2022. Patients who had pulmonary symptoms, required prolonged oxygen therapy, and/or had restrictive pulmonary function test (PFT) and/or DLCO <80%, with diffuse parenchymal involvement on high-resolution computed tomography (HRCT), were given immunosuppressive treatment with methylprednisolone and/or mycophenolate mofetil (MMF) and followed up for 6 months. Results: Among the 48 patients, 35 were treated. Two patients were excluded due to discontinued treatment and passed away before the study period ended. Of 33 cases, 21 (66.6%) were treated with methylprednisolone, 11 (33%) with methylprednisolone + MMF, and 1 (0.4%) with MMF alone. Comparing baseline and 6th-month data revealed significant improvement in mMRC score, saturation (SpO2), FVC, FVC%, FEV%, and DLCO% values (p<0.005). While regression was observed in all radiologic findings, regression in ground glass and reticulation was statistically significant (p<0.005). When the 1st and 6th-month data were compared, a significant increase was observed in SpO2 and DLCO% values (p=0.016) and there was a significant regression in reticulation radiologically (p=0.01).Conclusions: Long-term immunosuppressive therapy may be preferred in proper cases of post-COVID-19-ILD as an effective and safe treatment option that improves the quality of life, respiratory parameters, and radiologic findings.
References
Guler SA, Ebner L, Aubry-Beigelman C, et al. Pulmonary function and radiological features 4 months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4). doi:10.1183/13993003.03690-2020
Touman A, Kahyat M, Bulkhi A, et al. Post COVID-19 chronic parenchymal lung changes. Cureus. 2022;14(5). doi:10.7759/cureus.25197
Dhooria S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J. 2022;59(2). doi:10.1183/13993003.02930-2021
Demirkol B, Gül Ş, Çörtük M, et al. Clinical reflection of pre- and post-COVID-19 symptoms in COVID-19 patients. Hamidiye Med J. 2022;3(2):153-158. doi:10.4274/hamidiyemedj.galenos.2022.18480
Adler L, Gazit S, Pinto Y, et al. Long-COVID in patients with a history of mild or asymptomatic SARS-CoV-2 infection: a Nationwide Cohort Study. Scand J Prim Health Care. 2022;0(0):1-8. doi:10.1080/02813432.2022.2139480
Fernández-De-las-peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining post-covid symptoms (Post-acute covid, long covid, persistent post-covid): an integrative classification. Int J Environ Res Public Health. 2021;18(5):1-9. doi:10.3390/ijerph18052621
Lerum TV, Aaløkken TM, Brønstad E, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4). doi:10.1183/13993003.03448-2020
Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post–COVID-19 interstitial lung disease: an observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799-806. doi:10.1513/AnnalsATS.202008-1002OC
Segala FV, Sgalla G, Salvati F, et al. Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure. 2021;187(october):106571.
Williams N. The MRC breathlessness scale. Occup Med (Chic Ill). 2017;67(6):496-497. doi:10.1093/occmed/kqx086
Graham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of spirometry 2019 update. an official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70. doi:10.1164/RCCM.201908-1590ST
Wei J, Yang H, Lei P, et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J Xray Sci Technol. 2020;28(3):383-389. doi:10.3233/XST-200685
Demircioglu O, Kocakaya D, Cimsit C, Cimsit NC. New grading system for post-COVID-19 pulmonary fibrosis based on computed tomography findings. Med (United States). 2022;101(35):E30146. doi:10.1097/MD.0000000000030146
Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med. 2022;(Ild). doi:10.1007/s00134-022-06877-w
Martino GP, Benfaremo D, Bitti G, et al. 6 and 12 month outcomes in patients following COVID ‑ 19 ‑ related hospitalization : a prospective monocentric study. Intern Emerg Med. 2022;17(6):1641-1649. doi:10.1007/s11739-022-02979-x
Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19 : a longitudinal cohort study. Lancet. 2021;398(10302):747-758. doi:10.1016/S0140-6736(21)01755-4
Vasarmidi E, Ghanem M, Crestani B. Interstitial lung disease following coronavirus disease 2019. Curr Opin Pulm Med. 2022;28(5):399-406. doi:10.1097/MCP.0000000000000900
Funke-Chambour M, Bridevaux PO, Clarenbach CF, et al. Swiss recommendations for the follow-up and treatment of pulmonary. Respiration. 2021;100(8):826-841. doi:10.1159/000517255
Günay S, Parlak İS, Hezer H, et al. Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy : 3-month follow-up. Sarcoidosis Vasc Diffus Lung Dis. 2023;40(3):e2023029.
Kostorz-Nosal S, Jastrzębski D, Chyra M, Kubicki P, Zieliński M, Ziora D. A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia. Eur Clin Respir J. 2021;8(1). doi:10.1080/20018525.2021.1945186
Morisset J, Johannson KA, Vittinghoff E, et al. Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest. 2016;151(3):619-625. doi:10.1016/j.chest.2016.10.029
Fiddler CA, Simler N, Parfrey H. Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis - A single ‐ centre experience. 2019;(August):1-4. doi:10.1111/crj.13086
van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis. 2022;16(16):175346662211170. doi:10.1177/17534666221117002
Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med. 2020;383(10):958-968. doi:10.1056/nejmra2005230
Paul C, Lin-Shaw A, Joseph M, Kwan K, Sergiacomi G, Mura M. Successful treatment of fibrosing organising pneumonia causing respiratory failure with mycophenolic acid. respiration. 2016;92(4):279-282. doi:10.1159/000448846
Tan HX, Wong CK, Yik WF, Lam YF, Lachmanan KR. Post COVID‐19 organizing pneumonia treated with mycophenolate mofetil. Respirol Case Reports. 2022;10(11). doi:10.1002/rcr2.1042
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Sule Gul, Barış Demirkol, Ramazan Eren, Kursad Nuri Baydili, Burcu Babaoğlu Elkhatroushi, Şerife Nur Ulusan, Umut İlhan, Mustafa Çörtük, Erdoğan Çetinkaya
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
